Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Current Assets (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Current Assets for 4 consecutive years, with $301.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 42.23% to $301.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $301.4 million through Dec 2025, up 42.23% year-over-year, with the annual reading at $301.4 million for FY2025, 42.23% up from the prior year.
  • Current Assets for Q4 2025 was $301.4 million at LENZ Therapeutics, up from $207.0 million in the prior quarter.
  • The five-year high for Current Assets was $343.8 million in Q1 2022, with the low at $197.9 million in Q1 2025.
  • Average Current Assets over 4 years is $251.5 million, with a median of $238.8 million recorded in 2023.
  • The sharpest move saw Current Assets fell 23.11% in 2023, then skyrocketed 42.23% in 2025.
  • Over 4 years, Current Assets stood at $275.4 million in 2022, then fell by 13.28% to $238.8 million in 2023, then dropped by 11.25% to $211.9 million in 2024, then skyrocketed by 42.23% to $301.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $301.4 million, $207.0 million, and $213.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.